Specialty drugs are typically associated with high-cost, complex, or rare health care conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Specialty drug products are a high-cost, inflationary drug trend that is expected to drive a significant portion of future drug costs, but specialty drugs do not currently have a universal definition or drug cost and claim benchmarks.
This study provides employers and health plans with specialty drug claim cost benchmarks, to allow them to better understand the magnitude and distribution of these costs. It also highlights opportunities for health care organizations to better manage the total specialty drug trend.
This study was commissioned by Novologix, Inc.